Bridgeway Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Bridgeway Capital Management’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-223,500	Closed	-$44K	–	1431
2019 Q1	$44K	Hold	223,500	–	–	﹤0.01%	1316
2018 Q4	$156K	Hold	223,500	–	–	﹤0.01%	1252
2018 Q3	$275K	Buy	+223,500	New	+$250K	﹤0.01%	1267
2017 Q2	–	Sell	-187,500	Closed	-$349K	–	1498
2017 Q1	$349K	Hold	187,500	–	–	﹤0.01%	1171
2016 Q4	$971K	Hold	187,500	–	–	0.01%	833
2016 Q3	$1.04M	Buy	187,500 +30,000	+19%	+$171K	0.02%	776
2016 Q2	$874K	Buy	157,500 +38,500	+32%	+$202K	0.01%	829
2016 Q1	$524K	Hold	119,000	–	–	0.01%	1027
2015 Q4	$716K	Hold	119,000	–	–	0.01%	908
2015 Q3	$931K	Hold	119,000	–	–	0.02%	774
2015 Q2	$729K	Buy	119,000 +40,000	+51%	+$310K	0.01%	906
2015 Q1	$636K	Buy	79,000 +8,614	+12%	+$65K	0.01%	988
2014 Q4	$356K	Sell	70,386 -9,614	-12%	-$47.5K	0.01%	1176
2014 Q3	$415K	Hold	80,000	–	–	0.01%	1168
2014 Q2	$622K	Hold	80,000	–	–	0.02%	985
2014 Q1	$558K	Buy	80,000 +40,000	+100%	+$312K	0.02%	1022
2013 Q4	$240K	Sell	40,000 -29,400	-42%	-$192K	0.01%	1263
2013 Q3	$541K	Buy	69,400 +15,000	+28%	+$69.6K	0.02%	997
2013 Q2	$207K	Buy	+54,400	New	+$223K	0.01%	1264

Other funds holding GNMX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AMCA

Arthur M. Cohen & Associates Northbrook, Illinois $640M AUM 26.68% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Bridgeway Capital Management's GNMX Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2019, closing a stake of 223,500 shares — an estimated $44K sold.

Bridgeway Capital Management first reported a position in GNMX in Q2 2013 and held it in 19 quarters. The position peaked at $1.04M in Q3 2016. 29 funds tracked by Wall St. Rank hold GNMX as of Q2 2019.

Bridgeway Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 223,500 Aevi Genomic Medicine Inc shares in Q2 2019, an estimated $44K.
Bridgeway Capital Management first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 19 quarters.
Bridgeway Capital Management's Aevi Genomic Medicine Inc position peaked at $1.04M in Q3 2016.
29 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.